BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of BioLineRx in a research note on Wednesday, November 6th.

BioLineRx Stock Up 3.9 %

Shares of BioLineRx stock opened at $0.29 on Friday. BioLineRx has a 1 year low of $0.25 and a 1 year high of $1.89. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The company has a 50-day moving average of $0.48 and a 200 day moving average of $0.61. The firm has a market cap of $22.94 million, a price-to-earnings ratio of -1.27 and a beta of 1.48.

Institutional Trading of BioLineRx

Several institutional investors have recently bought and sold shares of BLRX. PVG Asset Management Corp purchased a new position in BioLineRx in the second quarter worth about $70,000. CVI Holdings LLC purchased a new stake in shares of BioLineRx during the second quarter valued at approximately $462,000. Finally, Atria Investments Inc increased its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.